Seeking Alpha

BioCryst Pharmaceuticals (BCRX) soars 16.4% in premarket trading after reporting favorable...

BioCryst Pharmaceuticals (BCRX) soars 16.4% in premarket trading after reporting favorable results on testing of its hepatitis C treatment BCX5191. The preclinical study showed that BCX5191 demonstrates high oral bioavailability and is actively transported into the liver.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|